Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2011
Filed with the SEC on Feb 22, 2012 and accepted by EDGAR at Feb 22, 2012, 22:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2011-10-01 to 2011-12-31 | $563.3m | us-gaap:Revenues |
| Revenue | 12 months2011-01-01 to 2011-12-31 | $1.41bn | us-gaap:Revenues |
| Cost of revenue | 3 months2011-10-01 to 2011-12-31 | $22.9m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 12 months2011-01-01 to 2011-12-31 | $63.6m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2011-10-01 to 2011-12-31 | $186.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2011-01-01 to 2011-12-31 | $707.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2011-10-01 to 2011-12-31 | $121.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2011-01-01 to 2011-12-31 | $400.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2011-10-01 to 2011-12-31 | $223.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2011-01-01 to 2011-12-31 | $113.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2011-10-01 to 2011-12-31 | $12.4m | us-gaap:InterestExpense |
| Interest expense | 12 months2011-01-01 to 2011-12-31 | $38.5m | us-gaap:InterestExpense |
| Income tax | 3 months2011-10-01 to 2011-12-31 | $22.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2011-01-01 to 2011-12-31 | $19.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2011-10-01 to 2011-12-31 | $158.6m | us-gaap:NetIncomeLoss |
| Net income | 12 months2011-01-01 to 2011-12-31 | $29.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2011-10-01 to 2011-12-31 | $0.74 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2011-01-01 to 2011-12-31 | $0.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2011-10-01 to 2011-12-31 | $0.76 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2011-01-01 to 2011-12-31 | $0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2011-10-01 to 2011-12-31 | 217,602,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2011-01-01 to 2011-12-31 | 208,807,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 12 months2011-01-01 to 2011-12-31 | $34.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2011-12-31 | $475.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2011-12-31 | $1.33bn | us-gaap:AssetsCurrent |
| Total assets | At period end2011-12-31 | $2.20bn | us-gaap:Assets |
| Current liabilities | At period end2011-12-31 | $392.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2011-12-31 | $1.24bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2011-12-31 | $786.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001047469-12-001298. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.